US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Mace Security International, Inc.

0.0157

0.0000

Volume:- -

Turnover:- -

Market Cap:1.04M

PE:-0.40

High:0.0157

Open:0.0157

Low:0.0157

Close:0.0157

52wk High:0.0157

52wk Low:0.0157

Shares:66.60M

Float Shares:61.22M

Volume Ratio:0.11

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0391

EPS(LYR):-0.0309

ROE:-106.94%

ROA:-19.75%

PB:0.51

PE(LYR):-0.51

Loading ...

Overview Company News Filings

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

The Future is Here: How Oral Semaglutide is Reshaping the Value of Diabetes Treatment

Akebia Announces Establishment of Rare Kidney Disease Pipeline

iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR Multicenter Randomized Controlled Trial

Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MACE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MACE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","market":"US","secType":"STK","nameCN":"Mace Security International, Inc.","latestPrice":0.01568,"timestamp":1771621200000,"preClose":0.01568,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61215490,"shares":66596075,"eps":-0.039075,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":0.01568,"high":0.01568,"low":0.01568,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039075,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.01568,"volumeRatio":0.10668023659160104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","floatShares":61215490,"roa":"-19.75%","roe":"-106.94%","lyrEps":-0.030906,"volumeRatio":0.10668023659160104,"shares":66596075,"dividePrice":0,"high":0.01568,"amplitude":0,"preClose":0.01568,"low":0.01568,"week52Low":0.01568,"pbRate":"0.51","psRate":"0.18","week52High":0.01568,"institutionHeld":0.0001,"latestPrice":0.01568,"eps":-0.039075,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.039075,"open":0.01568,"prevYearClose":0.01568,"prevWeekClose":0.0157,"prevMonthClose":0.0157,"prevQuarterClose":0.0157,"fiveDayClose":0.0157,"twentyDayClose":0.0157,"sixtyDayClose":0.0157},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MACE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-09","symbol":"MACE","reason":null,"defaultRemindTime":1733754600000,"announcedDate":"2024-12-06","type":"delisting","dateTimestamp":1733720400000},{"market":"US","date":"2024-09-30","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1727668800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-02","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1712030400000,"reportTimeType":"","actualEps":null},{"date":"2023-11-14","symbol":"MACE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1699995600000,"name":null,"time":"Post Market","dateTimestamp":1699938000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MACE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MACE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MACE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591825579","title":"BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2591825579","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591825579?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890000,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec.  16, 2025  (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206152/0/en/BioCardia-Cell-Therapy-for-Ischemic-Heart-Failure-to-Progress-to-Formal-Clinical-Consultation-with-Japan-PMDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2637428348.USD","BK4139","BK4183","LU0738911758.USD","BCDA","LU0661504455.SGD","LU1894683348.USD","BK4157","LU0949170772.SGD","MACE","LU0545039389.USD","LU2065732104.USD","CMS","BK4208","PRGS","LU0553294199.USD","BK4097","BK4588","LU2500361329.USD","BK4585","LU2346227817.USD","LU1894683264.USD","LU1003077747.HKD"],"gpt_icon":0},{"id":"1115285449","title":"The Future is Here: How Oral Semaglutide is Reshaping the Value of Diabetes Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1115285449","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115285449?lang=en_us&edition=fundamental","pubTime":"2025-12-10 16:54","pubTimestamp":1765356880,"startTime":"0","endTime":"0","summary":"A recent study published in *Military Medical Research* by the China CDC's Chronic Disease Center has sounded the alarm on diabetes prevalence and its non-fatal burden in China. Without effective...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","BK4183","MACE"],"gpt_icon":0},{"id":"2588223127","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223127?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4213","IE00BLDYK493.USD","BK4181","BK4161","BK4077","FSGS","MI","LU2065731478.USD","LU1169590202.USD","IE00B64QTZ34.USD","APA","LU1169589451.USD","BK4585","RBC","PD","BK4157","BK4023","PK","MACE","BK4218","BK4588","LU0256331488.USD"],"gpt_icon":0},{"id":"2582361020","title":"iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361020","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361020?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:05","pubTimestamp":1762866300,"startTime":"0","endTime":"0","summary":"Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio long-term contin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/11/3185387/0/en/iRhythm-Technologies-Announces-Publication-of-Large-Scale-Study-in-Heart-Rhythm-and-New-Data-Presented-at-AHA-Scientific-Sessions-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","HE","BK4157","BK4082","BK4563","BK4231","MACE","BK4080","SRC","BK4081","IRTC"],"gpt_icon":0},{"id":"2582872883","title":"CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872883","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872883?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"-Positive Phase 1 data for CTX310 presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184507/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","CAT","LU1035775433.USD","LU0234570918.USD","BK4149","LU1674673691.USD","LU0963586101.USD","IE00B2B36J28.USD","LU2237438978.USD","BK4109","LU1778281490.HKD","FXI","AHP","BK4153","LU0417517546.SGD","LU0889565916.HKD","CAR","LU1585245621.USD","IE00BZ9MQY76.HKD","LDL","LU2236285917.USD","LU1988902786.USD","IE0009355771.USD","LU0061475181.USD","SCD","LU2362540622.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1917777945.USD","BK4588","LU2456880835.USD","MACE","TG","LU0079474960.USD","LU0942090050.USD","VRTX","KSA","BK4597","LU2463526074.USD","LU0566484027.USD","SLE","LU2324357040.USD","VERX","CRSP","LU0432979614.USD","LU1430594728.SGD","LU1559883803.SGD","ASH","UAE","LU1861559042.SGD"],"gpt_icon":0},{"id":"2582879368","title":"Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879368?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"Vafseo (vadadustat) Q3 2025 net product revenues grew to$14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth qu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184392/37519/en/Akebia-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RBC","BK4077","BK4183","AKBA","LU2065731478.USD","MI","IE00BLDYK493.USD","USRC","IE00B64QTZ34.USD","BK4161","BK4157","MACE"],"gpt_icon":0},{"id":"2581042806","title":"Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581042806","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581042806?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:30","pubTimestamp":1762471800,"startTime":"0","endTime":"0","summary":"Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025CAMBRIDGE, Mass., Nov.  06, 2025  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3183315/37519/en/Vafseo-vadadustat-Dialysis-Dependent-Patient-Post-Hoc-Data-Analysis-Composite-of-All-Cause-Mortality-and-Hospitalization-Outcomes-Statistically-More-Favorable-for-Patients-Receivin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MI","IE00BLDYK493.USD","BK4161","POST","BK4183","RBC","LU2065731478.USD","IE00B64QTZ34.USD","BK4157","BK4077","BK4212","MACE"],"gpt_icon":0},{"id":"2580295752","title":"TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR Multicenter Randomized Controlled Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580295752","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580295752?lang=en_us&edition=fundamental","pubTime":"2025-11-03 18:04","pubTimestamp":1762164240,"startTime":"0","endTime":"0","summary":"SHANGHAI, Nov. 3, 2025 /PRNewswire/ --The 37th Annual Transcatheter Cardiovascular Therapeutics  symposiumwas held grandly in San Francisco, USA, attracting widespread attention from the global cardiovascular community. On the morning of October 28th , during the \"Innovation Session: Robotics and AI-Enhanced Interventions,\" Dr. Wang Rui, representing the team of Academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University, presented to the world for the first time the safety and efficacy data from the multicenter randomized controlled trial of China's independently developed PANVIS STAR Vascular Interventional Surgery Control System. The results were encouraging ——in the field of Percutaneous Coronary Intervention , the introduction of robotic technology is gradually transforming traditional surgical paradigms.This prospective, multicenter, randomized controlled trial, led by Principal Investigator Academician Ge Junbo, aimed to evaluate the safety and efficacy of PANVIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/tct-2025--robot-assisted-pci-enters-a-new-era-results-of-the-panvis-star-multicenter-randomized-controlled-trial-302602339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","MACE","PCI","PCI.AU","BK4183"],"gpt_icon":0},{"id":"2580671442","title":"Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2580671442","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580671442?lang=en_us&edition=fundamental","pubTime":"2025-11-03 16:48","pubTimestamp":1762159680,"startTime":"0","endTime":"0","summary":"Wegovy  is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health condition.In Hong Kong, with over 30% of adults classified as obese[1] and 20% of adolescents being overweight or obese[2], Wegovy offers an effective treatment option to help combat the rising health burden.The launch of Wegovy in Hong Kong extends Novo Nordisk's commitment to addressing obesity as a chronic disease through clinically proven treatments.HONG KONG, Nov. 3, 2025 /PRNewswire/ --Leading global healthcare company Novo Nordisk announces the launch of Wegovy in Hong Kong, now available at private clinics and selected pharmacies. Clinically proven for long-term weight management,Wegovy represents a significant step forward in addressing the city's escalating health burden through evidence-based care for ","market":"other","thumbnail":"https://mma.prnewswire.com/media/2810055/image_964286_13480542.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2810055/image_964286_13480542.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/novo-nordisk-launches-wegovy-in-hong-kong-for-weight-management-302602289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4532","BK4599","BK4585","BK4007","BK4588","LU1093756325.SGD","NVO","BK4157","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD","MACE","BK4183"],"gpt_icon":1},{"id":"2564807570","title":"Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807570","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807570?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:30","pubTimestamp":1756816200,"startTime":"0","endTime":"0","summary":"Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of ageTHE WOODLANDS, Texas, Sept.  02, 2025  (GLOBE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142691/0/en/Sotagliflozin-Provides-Consistent-Relative-Risk-Reduction-in-Heart-Failure-and-Major-Cardiovascular-Events-Across-All-Age-Ranges-Including-Greater-Than-75-in-Data-Presented-at-the-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","CV","BK4588","BK4183","BK4082","HCM","MACE","BK4157","HF","BK4007","BK4585","CSII"],"gpt_icon":0},{"id":"2563885041","title":"New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2563885041","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563885041?lang=en_us&edition=fundamental","pubTime":"2025-08-30 20:30","pubTimestamp":1756557000,"startTime":"0","endTime":"0","summary":"-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRID","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/30/3141868/18362/en/New-REDUCE-IT-Analyses-Presented-at-ESC-2025-Include-Data-Showing-VASCEPA-VAZKEPA-Icosapent-Ethyl-Therapy-Resulted-in-9-Fewer-Total-Hospitalizations-Reduces-Cardiovascular-Disease-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","OR","BK4139","BK4161","BK4183","BK4157","TSS","BK4082","BK4604","ARR","TG","BK4110","AMRN","IPE","HR","RRR","CSII","BK4150","BK4203","BK4153","BK4090","MACE","BK4225"],"gpt_icon":1},{"id":"2562124977","title":"New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2562124977","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562124977?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:00","pubTimestamp":1756123200,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Aug.  25, 2025  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/25/3138380/18362/en/New-Analyses-from-REDUCE-IT-and-EPA-Mechanistic-Data-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","IPE","BK4090","BK4153","BK4082","MACE","BK4139","CV","BK4157","BK4183","TG"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}